CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.1% Today

What is CRISPR Therapeutics AG?

CRISPR Therapeutics (CRSP) is a gene-editing firm focused on developing innovative therapies using CRISPR technology. The company has been making strides in its gene-editing programs and has a positive pipeline of treatments.

Why is CRISPR Therapeutics AG going down?

CRSP stock is down 5.1% on Mar 12, 2026 13:50

• The increase in the convertible notes offering from $350 million to $550 million indicates strong investor demand and a strategic move to bolster financial flexibility for CRISPR Therapeutics.
• Cathie Wood's ARK Invest buying a significant stake in CRSP suggests confidence in the long-term potential of the company despite the bearish market movement.
• The stock's 12% decline following the convertible notes announcement may be attributed to short-term concerns about potential shareholder dilution, although analysts view this as a buying opportunity for investors with a higher risk tolerance.
• Overall, the market reaction seems to be a mix of short-term profit-taking due to fundraising news and long-term optimism about CRISPR Therapeutics' gene-editing platform and drug pipeline.

CRSP Price Chart

CRSP Technical Analysis

CRSP News

Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million

CRISPR Therapeutics initially launched a private $350 million convertible notes offering on March 10, 2026. Due to strong investor demand, the company upsized the offering to $550 million on March 11, 2026, to strengthen its financial flexibility and support its gene-editing programs. TipRanks' AI Analyst, Spark, rates CRSP as "Neutral" due to weak financial performance and a bearish technical setup, despite a strong balance sheet and positive pipeline updates.

https://www.tipranks.com/news/company-announcements/crispr-therapeutics-upsizes-convertible-notes-offering-to-550-million

CRISPR Therapeutics AG Prices $550 Million Convertible Senior Notes Offering Due 2031

CRISPR Therapeutics AG has priced a $550 million private offering of convertible senior notes due in 2031, upsized from an initial $350 million, with proceeds for general corporate purposes. The notes carry a coupon rate of 1.125% (adjusted to 1.7308% due to Swiss tax withholding) and can be converted into common shares at approximately $76.56 per share. The offering is expected to close on March 16, 2026, providing significant capital to advance the company's gene-editing platform.

https://www.quiverquant.com/news/CRISPR+Therapeutics+AG+Prices+%24550+Million+Convertible+Senior+Notes+Offering+Due+2031

Cathie Wood buys the dip in gene-editing firm CRISPR Therapeutics (CRSP:NASDAQ)

Cathie Wood's ARK Invest has bought a significant stake in gene-editing firm CRISPR Therapeutics (CRSP) by purchasing over 280,000 shares worth approximately $14.82 million. This move is part of ARK Invest's strategy to add to beaten-down technology and biotech names, while trimming other positions.

https://seekingalpha.com/news/4563025-cathie-wood-buys-the-dip-in-gene-editing-firm-crispr-therapeutics

This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday

CRISPR Therapeutics' stock plummeted over 12% today after the company announced its intention to issue $350 million worth of convertible notes to raise funds. While the market reacted negatively to the potential for shareholder dilution, this fundraising is typical for biotech startups and is expected to fuel the development of CRISPR's promising gene-editing drug pipeline, which includes an already approved gene therapy and five ongoing clinical trials. Analysts maintain a bullish stance on CRSP, suggesting this dip could be a buying opportunity for risk-tolerant investors.

https://www.fool.com/investing/2026/03/10/this-is-why-crispr-therapeutics-stock-is-tumbling/

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

CRISPR Therapeutics AG announced a proposed private offering of $350 million in convertible senior notes due 2031, with an option for initial purchasers to acquire an additional $52.5 million. The company plans to use the net proceeds for general corporate purposes. These notes will be senior, unsecured obligations and will not be registered under the Securities Act, making them available only through an exemption.

https://www.globenewswire.com/news-release/2026/03/10/3252625/0/en/crispr-therapeutics-announces-proposed-convertible-senior-notes-offering.html

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 20.2% Today

Ethereum ($ETH) Crypto Forecast: Up 11.6% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.3% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.8% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.2% Today

Intel Corporation ($INTC) Stock Forecast: Down 5.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 7.4% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.6% Today

Bumble Inc. ($BMBL) Stock Forecast: Up 5.6% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Up 5.1% Today

CRISPR Therapeutics AG Price History

13.01.2026 - CRSP Stock was up 11.3%

• Despite lower-than-anticipated Q4 revenue, CRISPR Therapeutics (CRSP) witnessed a significant upward trend in the market, reflecting investor confidence in the company's future prospects.
• The publication of the 2025 10-K report, outlining notable achievements and progress in its therapeutic initiatives, likely bolstered investor trust and contributed to the positive market movement.
• A favorable business update, highlighting advancements in various clinical programs and revenue growth associated with CASGEVY, may have eclipsed the Q4 revenue shortfall, fostering increased investor positivity.
• On the whole, the market dynamics indicate that investors are placing greater emphasis on CRISPR Therapeutics' upcoming potential and pipeline advancements rather than short-term financial performance, propelling the stock price upwards.

12.02.2026 - CRSP Stock was down 5.1%

• The increase in the convertible notes offering from $350 million to $550 million indicates strong investor demand and a strategic move to bolster financial flexibility for CRISPR Therapeutics.
• Cathie Wood's ARK Invest buying a significant stake in CRSP suggests confidence in the long-term potential of the company despite the bearish market movement.
• The stock's 12% decline following the convertible notes announcement may be attributed to short-term concerns about potential shareholder dilution, although analysts view this as a buying opportunity for investors with a higher risk tolerance.
• Overall, the market reaction seems to be a mix of short-term profit-taking due to fundraising news and long-term optimism about CRISPR Therapeutics' gene-editing platform and drug pipeline.

10.02.2026 - CRSP Stock was down 5.6%

• CRISPR Therapeutics AG (CRSP) is rated as a "Moderate Buy" by Wall Street analysts with a 17% upside potential. Nonetheless, certain AI stocks are viewed as having greater potential with lower risk, potentially drawing investor interest elsewhere.
• Investor attention is increasingly focused on CRSP's valuation, anticipating higher revenue from Casgevy but expressing concerns about significant company losses. The undervaluation potential noted in a discounted cash flow model adds a layer of complexity to the stock's current performance.
• Notable institutional holdings changes include SR One Capital Management LP boosting its stake by 94.4%, while Citigroup Inc. reduced its position by 59.3%. These contrasting actions suggest varying outlooks on CRSP's future.
• ARK Investment Management LLC trimmed its stake in CRSP by 3.9%, yet it remains the 8th largest position in its portfolio. This adjustment, along with other institutional investors and insider selling, likely contributed to today's bearish stock movement.

24.01.2026 - CRSP Stock was up 6.3%

• A notable acquisition of shares by O Neil Global Advisors Inc. suggests confidence in CRISPR Therapeutics' long-term potential, contributing to the bullish movement.
• The FDA's RMAT designation for zugo-cel and progress in the gene-editing pipeline are viewed as positive catalysts, overshadowing the wider losses reported by the company.
• A reduction in stake by Vestmark Advisory Solutions Inc. following an earnings miss and revenue decline may have initially raised concerns, but investors appear reassured by the focus on future clinical advancements and pipeline momentum.
• Insider selling by the General Counsel post-earnings report may have initially caused uncertainty, but overall market sentiment appears optimistic about CRSP's growth prospects.

11.01.2026 - CRSP Stock was down 6.2%

• Recent performance shows CRSP shares lagging by -18.7% over the past month compared to the Zacks S&P 500 composite, likely influencing the downward movement.
• CEO Samarth Kulkarni's sale of 60,000 shares, reducing his stake to 4.3% of the company, could suggest doubts about short-term performance.
• Despite favorable evaluations from analysts and institutions, uncertainties around forthcoming earnings and potential revenue growth in the upcoming fiscal year may have prompted profit-taking and the stock's bearish trajectory.

05.01.2026 - CRSP Stock was down 6.3%

• Despite optimistic expectations and the possibility of surpassing earnings projections, CRSP faced a bearish trend, potentially linked to investors taking profits following a recent price target increase.
• The expected decrease in earnings per share for the quarter may have also contributed to the negative market sentiment, as investors may have been looking for stronger financial results.
• Despite indicators like pipeline growth and strong institutional support, such as ARK Investment Management, pointing towards a promising future for the company, the current market reaction may stem from short-term worries or general market volatility.
• The bearish movement could also be influenced by the high-risk nature of gene-editing technologies and the uncertainties surrounding the company's ongoing projects and financial results.

05.02.2026 - CRSP Stock was down 5.3%

• An increased stake by Vanguard Group Inc. amidst CRISPR Therapeutics missing quarterly earnings and revenue expectations could indicate a lack of confidence in the company's short-term performance.
• A significant reduction in stake by Contrarius Group Holdings Ltd and TD Asset Management Inc. might suggest concerns about CRSP's future prospects or management decisions.
• Despite an increased stake by Rafferty Asset Management LLC, mixed analyst ratings and notable insider selling, including by the CEO, could be contributing to the bearish movement in CRSP's stock price.
• The overall market sentiment seems to be cautious towards CRISPR Therapeutics AG due to the company's recent financial performance and insider activities, overshadowing its potential future growth prospects highlighted in the Simply Wall St analysis.

26.01.2026 - CRSP Stock was up 2.8%

• Despite recording a substantial year-over-year decline in earnings and revenue in Q4, CRISPR Therapeutics AG saw a bullish market shift.
• Institutional investors such as O Neil Global Advisors Inc. purchased a large number of shares, indicating confidence in the company's future prospects.
• The FDA's approval of zugo-cel as a Regenerative Medicine Advanced Therapy (RMAT) and the launch of Casgevy are viewed as pivotal factors driving positive investment sentiment, overshadowing concerns about widening net losses.
• Varied analyst ratings and insider selling may have introduced some volatility, but overall, market attention appears to be more drawn towards the company's pipeline progress and upcoming milestones rather than its current financial results.

06.01.2026 - CRSP Stock was up 5.1%

• Positive ratings from Citizens and Bank of America suggest an undervalued pipeline with potential for late-stage development, leading to investor optimism.
• Expectations of CRSP surpassing earnings estimates for the quarter ending December 2025, along with a positive price target increase, have likely boosted investor confidence.
• Collaboration revenues from partnerships and the anticipated performance in the upcoming earnings report are driving the bullish momentum.
• Overall, the optimistic outlook on CRSP's pipeline, earnings performance, and institutional investor sentiment likely influenced today's strong bullish movement in the stock.

27.01.2026 - CRSP Stock was up 5.8%

• CRISPR Therapeutics' (CRSP) stock demonstrated a robust bullish trend today, posting a notable 11.85% increase despite the company's Q4 2025 earnings and revenue setbacks.
• Speculation surrounding potential acquisitions and the forthcoming investor conferences scheduled for March likely fueled the stock's impressive gain.
• The FDA's recognition of zugo-cel with the Regenerative Medicine Advanced Therapy (RMAT) designation, along with advancements in its gene-editing portfolio such as the commercial launch of Casgevy, have been regarded as favorable drivers for investors. These factors have overshadowed concerns related to widened net losses and internal selling activities.
• Despite lingering internal transactions and financial obstacles, the focus on future clinical progress and pipeline advancements appears to be influencing investor sentiment towards CRISPR Therapeutics. This highlights a preference for long-term growth prospects over immediate profitability considerations.

11.02.2026 - CRSP Stock was down 5.2%

• CRISPR Therapeutics' stock saw a notable decline of over 12% recently.
• Investor sentiment turned negative following the company's announcement of issuing $350 million in convertible notes to raise capital, raising concerns about potential dilution.
• Analysts, however, remain optimistic about CRSP, seeing the drop as a chance for bold investors to consider buying.
• The decision to issue convertible notes is customary in the biotech field to support research and development initiatives, showcasing CRISPR's dedication to advancing its gene-editing programs despite short-term market reactions.

30.00.2026 - CRSP Stock was down 5.5%

• Maintained a buy rating on CRSP but slightly lowered its price objective, citing revised projections for Casgevy 2026. This adjustment may have contributed to some uncertainty among investors.
• The Chief Marketing Officer's significant stock purchase indicates confidence in the company's future, contrasting with the stock's decline. This move might not have been sufficient to offset broader market sentiment.
• Despite positive strategic priorities announced by CRISPR Therapeutics, the stock underperformed the market, possibly due to analysts' concerns about upcoming earnings and revenue declines.
• Investor scrutiny following the CEO's share sale and Casgevy rollout may have added to the negative sentiment, with trimmed earnings estimates and highlighted execution risks impacting the stock's performance.